Join us at our new Singapore facility for an insightful seminar and roundtable discussion lead by industry thought leaders, Dr. Martin Wisher and Michael Payne. They will discuss regulatory issues and risk reduction strategies at this inaugural event. Space is limited for this exclusive event, so register today. Free.
|10.40 – 11.30|
Quality Control of Biological Medicinal Products - Developments in regulatory expectations and technical performance affecting companies in Asia
|Martin Wisher, Ph.D.|
|11.30 – 12.20||Helping Ensure Patient Safety through Risk Reduction, Biosafety Testing and Compliance|
|12.20 – 12.45||Roundtable Discussion|
|12.45 – 12.55||Closing Remarks|
|14.30 – 15.00||Registration|
|15.00 – 18.00||Opening Ceremony|
|(Seminar attendees and invited guests)|
With more than 30 years of experience in biologics quality control, assay and process validation, Dr. Wisher is well regarded in the biopharmaceutical, vaccine, gene and cell therapy industries. He has written numerous quality and regulatory articles and conducted biologics safety testing workshops and seminars around the world.
Dr. Wisher is currently Vice-Chairman of the Animal Cell Technology Industrial Platform (ACTIP) and has been a Chairman of the PDA Virus Spike Quality working group and a member of WHO and PDA working groups. He has held regulatory leadership positions in BioReliance®, recently acquired by Merck KGaA, Darmstadt, Germany, since 1990. He obtained his PhD in membrane biochemistry from the National Institute for Medical Research in London and subsequent further research on membrane receptors, monoclonal antibodies, and recombinant vaccines.
Michael Payne is the senior technical management biosafety consultant in Asia.He has worked in the pharmaceutical and biopharmaceutical industries for more than 30 years including 10 years in the U.S. as the head of global technical training. Michael is responsible for supporting compliance and best.
2 Science Park Drive
Ascent Building, Tower B, Level 04